Cross-sectional studies have found that an elevated ratio of arachidonic acid to omega-3 fatty acid is associated with depression, and controlled intervention studies have found that decreasing this ratio through administration of omega-3 fatty acids can alleviate depressive symptoms. Additionally, arachidonic acid and omega-3 fatty acids have opposing effects on inflammatory signaling. Exogenous administration of the inflammatory cytokine interferon-alpha (IFN-a) can trigger a depressive episode in a subset of vulnerable people, though associated risk factors remain poorly understood. Using a within-subject prospective design of 138 subjects, we examined whether baseline long-chain omega-3 (docosahexaenoic acid -DHA; eicosapentaenoic acid -EPA) and omega-6 (arachidonic acid -AA; di-homo-gamma-linolenic acid -DGLA) fatty acid status was associated with depression vulnerability in hepatitis C patients treated with IFN-a. Based on the literature, we had specific a priori interest in the AA/EPA + DHA ratio. Lower baseline DHA predicted depression incidence (p = 0.04), as did elevated DGLA (p = 0.02) and an elevated AA/ EPA + DHA ratio (p = 0.007). The AA/EPA + DHA ratio predicted depression even when controlling for other critical variables such as sleep quality and race. A higher AA/EPA + DHA ratio was positively associated with both increasing Montgomery-Asperg Depression Rating Scores over time (F = 4.0; p < 0.05) as well as interleukin-6 levels (F = 107.4; p < 0.05) but not C-reactive protein. Importantly, omega-3 and omega-6 fatty acid status was not associated with sustained viral response to IFN-a treatment. These prospective data support the role of fatty acid status in depression vulnerability and indicate a potential role for omega-3 fatty acids in the prevention of inflammation-induced depression.
Introduction
Emerging evidence suggests that elevated systemic inflammation may contribute to the pathoetiology of major depressive disorder (MDD) (Dowlati et al., 2010; Howren et al., 2009; Raison et al., 2006; Zorrilla et al., 2001) . Although there is accumulating evidence that a subset of MDD cases could be induced by inflammatory cytokines (Lotrich, 2012) , most people are resilient to elevated inflammatory activity and do not develop MDD. For example, exogenous administration of inflammatory cytokines such as interferon-alpha (IFN-a) can trigger depression, but only in a subset ($30%) of patients (Capuron et al., 2002; Capuron and Miller, 2004; Lotrich et al., 2007; Musselman et al., 2001) . While vulnerability factors for depression remain poorly understood, recent evidence has Polyunsaturated fatty acids (PUFAs) play a critical influence in the regulation of inflammatory signaling and potentially vulnerability to MDD. The long-chain omega-6 fatty acid arachidonic acid (AA; 20:4n-6) is a substrate for the synthesis of prostacyclins, thromboxanes, and prostaglandins such as PGE 2 . PGE 2 stimulates the synthesis of inflammatory cytokines (Portanova et al., 1998; Wang et al., 2010) ; and in turn prostaglandins may also be important in mediating the effect of peripheral inflammation on brain function. For example, inhibition of cyclooxygenase-2 (COX-2), the rate-limiting enzyme in the conversion of AA to PGE 2 , can attenuate lipopolysaccharide (LPS)-induced increases in extra-cellular hippocampal serotonin (Linthorst et al., 1996) . Moreover, adjunctive treatment with celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor,
